Korean Ministry OKs Peptron’s P2 clinical trial of Parkinson’s disease treatment

[Farooqji]

The company expects to complete the trial by 2020 and will evaluate the efficacy and safety of PT320 for symptom improvement and Parkinson's disease inhibition in patients with early Parkinson's disease at the Seoul National University Hospital and Asan Medical Center.

m.koreabiomed.com/news/arti...

[Farooqji]

from peptron website

" Peptron has developed a sustained release formulation of exenatide (PT302), for example, once weekly or once every two weeks injectable forms which already tested in type 2 diabetic patients. In 2014, Peptron licensed in the exclusive right of the National Institutes of Health(NIH) patent for the use of GLP-1 agonists for the treatment of neurodegenerative diseases including Parkinson’s disease and has been focused on the clinical development of PT302.

The manufacturing facility was constructed in 2018 which will produce the investigational medical product for the Phase 2 clinical with Parkinson’s disease. To strengthen intellectual properties rights, Peptron has collaborated with NIH to produce more patents and publications supporting the scientific background of the use of GLP-1 agonists in CNS fields.

We believe PT302 holds potential to slow the progress of the disease itself, not merely mitigate the symptoms. In addition, it will provide the expansion of indications to the most of CNS disorders including AD, and patient compliances."